Omalizumab beneficial in patients with moderate to severe allergic asthma regardless of BMI: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-03-01 03:30 GMT   |   Update On 2023-10-07 11:26 GMT
Advertisement

Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma by Bob Geng, et al. published in the Annals of Allergy, Asthma & Immunology.

Effectiveness of asthma treatment, including biologics, may be different in patients with higher body mass index (BMI).

Researchers examined response to omalizumab (dosed by serum immunoglobin E level and weight) by BMI category.

Advertisement

Pooled data from 2 randomized, double-blind, placebo-controlled studies of adults with moderate-to-severe allergic asthma were analyzed by BMI category (<25 kg/m 2 [normal/underweight], n = 397; 25 to <30 kg/m 2 [overweight], n = 330; ≥30 kg/m 2 [obese], n = 268). Placebo-adjusted exacerbation rate reductions were assessed by Poisson regression modeling. Changes from baseline in forced expiratory volume in 1 second (FEV 1), beclomethasone dipropionate (BDP) dose, Total Asthma Symptom Score (TASS), and Asthma Quality of Life Questionnaire (AQLQ) were assessed by analysis of covariance.

Results of the study are:

Greater placebo-adjusted exacerbation rate reductions (95% confidence interval) were observed with increasing BMI (normal/underweight, −37.4% [−69.0%, 26.8%]; overweight, −52.7% [−78.4%, 3.7%]; obese, −71.9% [−86.9%, −39.5%]). There were no differences in FEV 1 improvement between BMI categories at week 16 (normal/underweight, 76.2 [5.3-147.1] mL; overweight, 98.1 [13.9-182.4] mL; obese, 69.1 [−18.9, 157.2] mL). No differences in BDP dose reduction (µg) were noted between BMI categories (normal/underweight, 23.0 [15.7-30.3]; overweight, 22.5 [13.5-31.5]; obese, 16.6 [5.8-27.3]). Fewer patients in the higher BMI categories eliminated BDP use. There were trends for smaller improvements with higher BMI in TASS (normal/underweight, −0.52 [−0.82, −0.22]; overweight, −0.50 [−0.80, −0.20]; obese, −0.39 [−0.77, 0.00]) and AQLQ (normal/underweight, 0.34 [0.16-0.52]; overweight, 0.34 [0.13-0.55]; obese, 0.15 [−0.08, 0.39]).

Thus, the researchers concluded that Omalizumab provides benefit to patients with moderate-to-severe allergic asthma, regardless of BMI.

Reference:

Omalizumab benefits patients with moderate to severe allergic asthma regardless of BMI, according to a recent study published in the Annals of Allergy, Asthma & Immunology.

https://www.annallergy.org/article/S1081-1206%2822%2900045-X/fulltext


Tags:    
Article Source : Annals of Allergy, Asthma & Immunology.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News